Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06429761
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-05-21
Brief Title:
A PROSPECTIVE MULTI-CENTER PHASE 4 STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-09-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-21
First Submit QC Date:
May 21 2024
Study First Post Date:
2024-05-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-21
Last Update Post Date:
2024-05-28
Last Update Post Date Type:
ACTUAL